{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:45:24Z","timestamp":1764153924202,"version":"3.46.0"},"reference-count":58,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Survivin (BIRC5) plays a key role in inhibiting apoptosis and is highly expressed in many cancers, including gliomas and breast cancer, where it contributes to tumor progression, therapeutic resistance and poor patient outcomes. With a dual function in promoting cell proliferation and survival, coupled with its potential immunogenicity, survivin is a compelling therapeutic target for cancer; yet, it has no FDA-approved agents to date. Here, we review key findings from preclinical models that emphasize how survivin contributes to chemoresistance and radioresistance; summarize the clinical landscape of survivin-targeted strategies, highlighting both the successes and limitations of these approaches; and outline next steps to optimize survivin-targeted therapies, including the need to integrate biomarker-focused patient selection and the potential for combination therapies. These insights establish survivin as a key driver of cancer progression and a promising target for future therapeutic development.<\/jats:p>","DOI":"10.3390\/ijms262311417","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:04:57Z","timestamp":1764151497000},"page":"11417","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Survivin: Now I Become Death, the Destroyer of Cells"],"prefix":"10.3390","volume":"26","author":[{"given":"Mia","family":"Fanuzzi","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3903-3080","authenticated-orcid":false,"given":"Shuhua","family":"Zheng","sequence":"additional","affiliation":[{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig M.","family":"Horbinski","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5871-977X","authenticated-orcid":false,"given":"Maryam A.","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrshavasan","family":"Congivaram","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-5196","authenticated-orcid":false,"given":"Ruochen","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashwat","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hurley","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-0677","authenticated-orcid":false,"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-0188","authenticated-orcid":false,"given":"Atique","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Brat","sequence":"additional","affiliation":[{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-5107","authenticated-orcid":false,"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-8695","authenticated-orcid":false,"given":"Amy B.","family":"Heimberger","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: A unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/HP.0000000000001601","article-title":"Radiation-induced cell death and its mechanisms","volume":"123","author":"Jiao","year":"2022","journal-title":"Health Phys."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41419-024-06559-z","article-title":"Cellular heterogeneity in TNF\/TNFR1 signalling: Live cell imaging of cell fate decisions in single cells","volume":"15","author":"Preedy","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7150\/jca.13332","article-title":"Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies","volume":"7","author":"Chen","year":"2016","journal-title":"J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","article-title":"Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics","volume":"14","author":"Mita","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrm3474","article-title":"The chromosomal passenger complex (CPC): From easy rider to the godfather of mitosis","volume":"13","author":"Carmena","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"F\u00e4ldt Beding, A., Larsson, P., Helou, K., Einbeigi, Z., and Parris, T.Z. (2022). Pan-cancer analysis identifies BIRC5 as a prognostic biomarker. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09371-0"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbrc.2010.03.165","article-title":"Regulation of survivin by PI3K\/Akt\/p70S6K1 pathway","volume":"395","author":"Zhao","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdj121","article-title":"Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1","volume":"17","author":"Ryan","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/sj.bjc.6600776","article-title":"Prognostic importance of survivin in breast cancer","volume":"88","author":"Kennedy","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_11","first-page":"359","article-title":"Survivin is a prognostic indicator in glioblastoma and may be a target of microRNA-218","volume":"18","author":"Tong","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.bjc.6602904","article-title":"Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma","volume":"94","author":"Xie","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00401-002-0532-x","article-title":"Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system","volume":"104","author":"Sasaki","year":"2002","journal-title":"Acta Neuropathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2002.20.4.1063","article-title":"Quantitatively determined survivin expression levels are of prognostic value in human gliomas","volume":"20","author":"Chakravarti","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_16","first-page":"100","article-title":"The role of survivin in diagnosis, prognosis and treatment of breast cancer","volume":"2","author":"Lv","year":"2010","journal-title":"J. Thorac. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/OP.23.00794","article-title":"Breast Cancer Brain Metastasis: A Comprehensive Review","volume":"20","author":"Raghavendra","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13058-024-01789-7","article-title":"Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review","volume":"26","author":"Wallace","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2021-6-6","article-title":"Leptomeningeal carcinomatosis and breast cancer: A systematic review of current evidence on diagnosis, treatment and prognosis","volume":"10","author":"Mollica","year":"2021","journal-title":"Drugs Context"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: A systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_22","unstructured":"WHO Classification of Tumours Editorial Board (2021). Central nervous system tumours. WHO Classification of Tumours Series, International Agency for Research on Cancer. [5th ed.]. Available online: https:\/\/publications.iarc.fr\/601."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12935-025-03680-7","article-title":"Triple-positive breast cancer: Navigating heterogeneity and advancing multimodal therapies for improving patient outcomes","volume":"25","author":"Xie","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14737140.2024.2373888","article-title":"First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor\/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC","volume":"24","author":"Peterlin","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/cas.14106","article-title":"Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma","volume":"110","author":"Shima","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1158\/1078-0432.CCR-22-2595","article-title":"Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase II trial","volume":"29","author":"Dorigo","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine-formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-013-1516-5","article-title":"Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors","volume":"63","author":"Lennerz","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","volume":"29","author":"Freeman","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-014-3238-6","article-title":"Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer","volume":"149","author":"Clemens","year":"2015","journal-title":"Breast Cancer Res Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1038\/sj.onc.1208049","article-title":"Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms","volume":"23","author":"Chakravarti","year":"2004","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bjc.6604160","article-title":"Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells","volume":"98","author":"Saito","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1158\/0008-5472.CAN-07-6441","article-title":"Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells","volume":"68","author":"Nandi","year":"2008","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yoo, J.-Y., Yeh, M., Wang, Y.-Y., Oh, C., Zhao, Z.-M., Kaur, B., and Lee, T.-J. (2021). MicroRNA-138 increases chemo-sensitivity of glioblastoma through downregulation of survivin. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070780"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/neuonc\/nov292","article-title":"MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints","volume":"18","author":"Wei","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Poon, M.T.C., Bruce, M., Simpson, J.E., Hannan, C.J., and Brennan, P.M. (2021). Temozolomide sensitivity of malignant glioma cell lines: A systematic review assessing consistencies between in vitro studies. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08972-5"},{"key":"ref_40","first-page":"vdae186","article-title":"Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma","volume":"6","author":"Dmello","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_44","first-page":"869","article-title":"Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients","volume":"61","author":"Andersen","year":"2001","journal-title":"Cancer Res."},{"key":"ref_45","first-page":"5964","article-title":"Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients","volume":"61","author":"Andersen","year":"2001","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5114\/aoms.2017.71069","article-title":"Antisense of survivin inhibits cervical cancer growth in mice","volume":"15","author":"Xu","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ferguson Bennit, H.R., Gonda, A., Kabagwira, J., Oppegard, L., Chi, D., Licero Campbell, J., De Leon, M., and Wall, N.R. (2021). Natural killer cell phenotype and functionality affected by exposure to extracellular survivin and lymphoma-derived exosomes. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031255"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"Nasrallah","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: A phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-020-04112-1","article-title":"Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI\u2013refractory advanced non-small cell lung cancer","volume":"86","author":"Shimizu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/cncr.26510","article-title":"A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma","volume":"118","author":"Cheson","year":"2012","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijrobp.2009.12.001","article-title":"Radiation-induced survivin nuclear accumulation is linked to DNA damage repair","volume":"77","author":"Capalbo","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.radonc.2011.06.037","article-title":"Survivin inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblastoma","volume":"101","author":"Reichert","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-20-1499","article-title":"Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic pontine glioma","volume":"27","author":"Chastkofsky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-015-3657-z","article-title":"Survivin contributes to DNA repair by homologous recombination in breast cancer cells","volume":"155","author":"Vequaud","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1158\/0008-5472.CAN-20-2931","article-title":"A spatial and functional interaction of a heterotetramer survivin-DNA-PKcs complex in DNA damage response","volume":"81","author":"Hehlgans","year":"2021","journal-title":"Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11417\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:09:29Z","timestamp":1764151769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":58,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262311417"],"URL":"https:\/\/doi.org\/10.3390\/ijms262311417","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}